These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 29102116)
1. Secretion of the Shiga toxin B subunit (Stx1B) via an autotransporter protein optimizes the protective immune response to the antigen expressed in an attenuated E. coli (rEPEC E22Ξ”ler) vaccine strain. Byrd W; Ruiz-Perez F; Setty P; Zhu C; Boedeker EC Vet Microbiol; 2017 Nov; 211():180-188. PubMed ID: 29102116 [TBL] [Abstract][Full Text] [Related]
2. Delivery of heterologous protein antigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbit enteropathogenic Escherichia coli. Zhu C; Ruiz-Perez F; Yang Z; Mao Y; Hackethal VL; Greco KM; Choy W; Davis K; Butterton JR; Boedeker EC Vaccine; 2006 May; 24(18):3821-31. PubMed ID: 16098637 [TBL] [Abstract][Full Text] [Related]
3. A directed intimin insertion mutant of a rabbit enteropathogenic Escherichia coli (REPEC) is attenuated, immunogenic and elicits serogroup specific protection. Ahmed S; Byrd W; Kumar S; Boedeker EC Vet Immunol Immunopathol; 2013 Mar; 152(1-2):146-55. PubMed ID: 23084628 [TBL] [Abstract][Full Text] [Related]
4. Towards a vaccine for attaching/effacing Escherichia coli: a LEE encoded regulator (ler) mutant of rabbit enteropathogenic Escherichia coli is attenuated, immunogenic, and protects rabbits from lethal challenge with the wild-type virulent strain. Zhu C; Feng S; Thate TE; Kaper JB; Boedeker EC Vaccine; 2006 May; 24(18):3845-55. PubMed ID: 16112258 [TBL] [Abstract][Full Text] [Related]
5. LEE-encoded regulator (Ler) mutants elicit serotype-specific protection, but not cross protection, against attaching and effacing E. coli strains. Zhu C; Feng S; Yang Z; Davis K; Rios H; Kaper JB; Boedeker EC Vaccine; 2007 Feb; 25(10):1884-92. PubMed ID: 17234305 [TBL] [Abstract][Full Text] [Related]
13. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Tsuji T; Shimizu T; Sasaki K; Tsukamoto K; Arimitsu H; Ochi S; Shimizu T; Taniguchi K; Noda M; Neri P; Mori H Vaccine; 2008 Apr; 26(17):2092-9. PubMed ID: 18387720 [TBL] [Abstract][Full Text] [Related]
14. Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B. Zhu C; Yu J; Yang Z; Davis K; Rios H; Wang B; Glenn G; Boedeker EC Clin Vaccine Immunol; 2008 Feb; 15(2):359-66. PubMed ID: 18003816 [TBL] [Abstract][Full Text] [Related]
15. A novel Salmonella strain inactivated by a regulated autolysis system and expressing the B subunit of Shiga toxin 2e efficiently elicits immune responses and confers protection against virulent Stx2e-producing Escherichia coli. Won G; Kim TH; Lee JH BMC Vet Res; 2017 Feb; 13(1):40. PubMed ID: 28143511 [TBL] [Abstract][Full Text] [Related]
16. Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. Keller R; Hilton TD; Rios H; Boedeker EC; Kaper JB Microb Pathog; 2010 Jan; 48(1):1-8. PubMed ID: 19878715 [TBL] [Abstract][Full Text] [Related]
17. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Liu J; Sun Y; Feng S; Zhu L; Guo X; Qi C Vaccine; 2009 Oct; 27(43):5929-35. PubMed ID: 19682616 [TBL] [Abstract][Full Text] [Related]
18. Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier. Buddenborg C; Daudel D; Liebrecht S; Greune L; Humberg V; Schmidt MA Int J Med Microbiol; 2008 Jan; 298(1-2):105-14. PubMed ID: 17936683 [TBL] [Abstract][Full Text] [Related]
19. Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice. Gu J; Ning Y; Wang H; Xiao D; Tang B; Luo P; Cheng Y; Jiang M; Li N; Zou Q; Mao X Vaccine; 2011 Oct; 29(43):7395-403. PubMed ID: 21807051 [TBL] [Abstract][Full Text] [Related]
20. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]